Skip to main content
Premium Trial:

Request an Annual Quote

Invitae Receives CAP Accreditation, Coverage Eligibility from Blue Shield of California and CMS

NEW YORK (GenomeWeb) – Invitae has received accreditation for its laboratory from the College of American Pathologists as well as coverage eligibility from Blue Shield of California and the Centers for Medicare and Medicaid Services, the company said this week.

"Securing reimbursement is an important step towards realizing our mission to make genetic testing affordable and accessible for patients,” Lisa Alderson, Invitae's chief commercial officer, said in a statement.

The CAP accreditation adds to the existing CLIA certification of Invitae's laboratory. The San Francisco-based company offers a clinical assay of 216 genes associated with 85 genetic disorders, which includes 17 targeted panels that focus on hereditary cancers, cardiology, hematology, neurology, and pediatrics.

According to its website, physicians in the US can order any combination of genes, disorders, and panels at a contract price of $1,500. The majority of Invitae's tests, which use next-generation sequencing technology, have a turnaround time of less than three weeks, according to the company.

This fall, Invitae completed a $120 million Series F financing round.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more